This CME Activity has expired and is no longer available for credit.
Achieving Treatment Success for Patients with Heart Failure Complicated by Hyponatremia
Time to Complete
November 27, 2012
October 14, 2014
1.50 / AMA PRA Category 1 Credit(s)TM 1.50 / CE for Nurses 1.50 / CE for Pharmacists
Jointly sponsored by The Foundation for Care Management and CME-University
This activity is supported by an educational grant from Otsuka America Pharmaceutical, Inc.
Hyponatremia is very difficult to treat in patients with heart failure, and improved treatment strategies represent an urgent clinical need. Recently, vasopressin has emerged as a therapeutic target in the management of hyponatremia. Vasopressin is a central modulator in hyponatremia, underscoring the importance of antagonizing vasopressin at its receptors in patients with hyponatremia and underlying heart failure. Guidelines for the treatment of hyponatremia have been published by several professional associations. The varying recommendations and emerging data on treatment options create challenges for practitioners caring for patients with hyponatremia. Recognizing the possible consequences of unmanaged hyponatremia in heart failure patients and implementing appropriate treatment strategies are critical steps toward improving outcomes in patients with hyponatremia.
This activity is intended for physicians, nurses, pharmacists, and other health professionals involved in the care of patients with heart failure.
Upon completion of this activity, participants should be able to:
Review the role of arginine vasopressin in the pathogenesis of hypervolemic hyponatremia in patients with heart failure
Assess the safety and efficacy of current and emerging therapies for the management of hyponatremia in patients with heart failure
Discuss evidence-based guidelines and strategies on the management of hypervolemic hyponatremia in acute decompensated heart failure
WELCOME AND INTRODUCTION John R. Teerlink, FACC, FAHA, FESC, FRCP — Course Chair Professor of Medicine, University of California, San Francisco (UCSF) Director, Heart Failure Program SFVAMC Director, Clinical Echocardiography, SFVAMC San Francisco VA Medical Center San Francisco, CA
John R. Teerlink, FACC, FAHA, FESC, FRCP I will not discuss off-label use or investigational use in my presentation. I have no financial relationships to disclose.
HYPERVOLEMIC HYPONATREMIA IN PATIENTS WITH HEART FAILURE: PATHOGENESIS AND TREATMENT OPTIONS Joseph G. Verbalis, MD Professor of Medicine and Physiology Chief, Division of Endocrinology and Metabolism Co-Director, Georgetown-Howard Universities Center for Clinical and Translational Science Georgetown University Medical Center Washington, DC
Joseph G. Verbalis, MD I will not discuss off-label use or investigational use in my presentation. I have financial relationships to disclose: Consultant/Advisory Board: Astellas, CardioKine, Otsuka America Pharmaceutical, and Sanofi-Aventis
LESSONS FROM CLINICAL TRIALS OF VASOPRESSIN RECEPTOR ANTAGONISTS IN HEART FAILURE Marvin A. Konstam, MD, FACC Professor of Medicine, Tufts University School of Medicine Chief Physician Executive of The Cardiovascular Center Tufts Medical Center Boston, MA
Marvin A. Konstam, MD, FACC I will not discuss off-label use or investigational use in my presentation. I have financial relationships to disclose: Consultant/Advisory Board: Astellas, CardioKine, Otsuka America Pharmaceutical, and Sanofi-Aventis
CURRENT GUIDELINES AND TREATMENT OPTIONS FOR IMPROVING OUTCOMES IN THE HEART FAILURE PATIENT WITH HYPONATREMIA Paul Hauptman, MD Professor of Internal Medicine, Division of Cardiology Assistant Dean, Clinical and Translational Research Saint Louis University Hospital Saint Louis, MO
Paul Hauptman, MD I will not discuss off-label use or investigational use in my presentation. I have financial relationships to disclose: Speaker Honorarium: Otsuka America Pharmaceutical Consultant/Advisory Board: Elsevier, BG Medical, and Otsuka America Pharmaceutical
CARING FOR HEART FAILURE PATIENTS WITH HYPONATREMIA: A NURSING PERSPECTIVE Linda J. Ordway, RN, MSN, ACNPc Nurse Practitioner Tufts Medical Center Boston, MA
Linda J. Ordway, RN, MSN, ACNPc I will not discuss off-label use or investigational use in my presentation. I have financial relationships to disclose: Speaker Honorarium: Otsuka America Pharmaceutical
AMA PRA Category 1 Credit(s)TM
The Foundation for Care Management (FCM) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
FCM designates this educational activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of the participation in the activity.
CE for Nurses
The Foundation for Care Management is an approved provider of continuing nursing education by the Washington State Nurses Association Continuing Education Approval & Recognition Program (CEARP), an accredited approver by the American Nurses Credentialing Center’s Commission on Accreditation.
CE for Pharmacists
The Foundation for Care Management is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. Program # 0347-9999-12-031-H01-P.
*This CE activity is knowledge-based.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Method of Participation: To receive continuing education credit, participants should review all program materials in their entirety, complete and submit the online post-test and evaluation, and score at least 70% on the post-test. A statement of credit will be available for printing upon successful completion.